References
- Wandinger KP, Saschenbrecker S, Stoecker W, et al. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol. 2011;231:86–91.10.1016/j.jneuroim.2010.09.012
- Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58:594–604.10.1002/ana.v58:4
- Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.10.1002/ana.v61:1
- Barry H, Byrne S, Barrett E, et al. Anti-N-methyl-D-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment. BJPsych Bull. 2015;39(1):19–23.10.1192/pb.bp.113.045518
- Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psych Rev. 2011;7(3):189–193.10.2174/157340011797183184
- Mann AP, Lukas RV, Grebenciucova E. Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management and challenges. Ther Clin Risk Manag. 2014;10:517–525.10.2147/TCRM
- De Scheerder MA, Rottey S, Mariman A, et al. How far to investigate presumed psychosomatic symptoms: lessons from a particular case…. Acta Clin Belg. 2017;72:138–141.10.1080/17843286.2016.1218178
- Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–165.10.1016/S1474-4422(12)70310-1
- Sienaert P, Dhossche DM, Vancampfort D, et al. A clinical review of the treatment of catatonia. Front Psych. 2014;5:1–9.